ロード中...
Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer
PURPOSE: The objectives of this analysis were to characterize the population pharmacokinetics (PK) of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) sourced from the European Union (bevacizumab-EU) in patients with advanced non-squamous non-small cell lung cancer (NSCL...
保存先:
| 出版年: | Cancer Chemother Pharmacol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7036079/ https://ncbi.nlm.nih.gov/pubmed/31768697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03946-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|